Piramal's Integrated Offerings
Abstract: Piramal Pharma Solutions is a contract development and manufacturing organization (CDMO), offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our clients through a globally integrated network of facilities in North America, Europe and Asia. This enables us to offer a comprehensive range of services including Drug Discovery Solutions, Process & Pharmaceutical Development services, Clinical Trial Supplies and Commercial supply of APIs and Finished dosage forms. We also offer specialized services like development and manufacture of Highly Potent APIs, Antibody Drug Conjugation and are well versed in technologies such as Bio-catalysis. Our capability as an integrated service provider & experience with various technologies enables us to serve Innovator and Generic companies worldwide. Our Development centers & Manufacturing sites have accreditation from regulatory bodies in US, Europe & Japan.
Description: Today many companies are strategically rationalizing their manufacturing and R&D operations and are increasingly exploring opportunities to expand outsourcing as well. With Piramals’ current structure, capabilities, and extensive offering, these macro trends complement the business model well, as customers are increasingly looking for more integrated outsourcing services. We are seeing a number of inquiries from companies looking for end-to-end project support. As integrated service needs continue to grow, we are well positioned to serve our client base as a trusted partner to reduce the burden of disease, by focusing on the three pillars that form Piramal: Customer Centricity, Quality, and Science. Many peers are either very focused on Europe & North America, or very India-centric. At Piramal, we have locations truly across the globe. While we act local, we think global, and are able to serve customers at their site of choice whilst providing a full portfolio of R&D and manufacturing.
Category: Drug Substance
Type: Small Molecules / Biologics
Contact: Michel Bulliard ([email protected])